Form 144: Markus Warmuth reports proposed sales

Rhea-AI Filing Summary

Form 144 filing reporting proposed sales and recent transactions by Markus Warmuth. The excerpt lists a proposed sale entry showing Common security lines and an RSU stock award granted 01/02/2025 with a related date 01/02/2026. The filing shows prior sales in the past three months with amounts 128372.00 and 153759.00 tied to Markus Warmuth, and an additional numeric line 97974.00 associated with a common security entry. The filing names Monte Rosa Therapeutics Inc and lists an address for Mr. Warmuth in Boston.

Insights

Compliance Attorney

Form 144 shows proposed sales and recent dispositions by an insider with RSU vesting dates recorded.

The excerpt lists proposed sale rows for a Common security and an RSU stock award with grant date 01/02/2025 and a related date 01/02/2026. It also records prior sales in the "Securities Sold During The Past 3 Months" section showing 128372.00 and 153759.00 associated with Markus Warmuth.

These entries are procedural disclosures under resale rules; timing, methods, and whether cash or shares exchanged are not specified in the excerpt. Subsequent filings or broker statements would state execution details and proceeds.

FAQ

What does the GLUE Form 144 disclose about Markus Warmuth's activity?

The filing discloses proposed sales and recent transactions by Markus Warmuth. It lists amounts 128372.00 and 153759.00 in the "Securities Sold During The Past 3 Months" section and identifies an RSU award with dates 01/02/2025 and 01/02/2026.

Which securities are listed on this Form 144 excerpt?

The excerpt lists a Common security entry and an RSU stock award. The RSU shows a grant date of 01/02/2025 with a related date 01/02/2026 and a quantity line of 21865 alongside a compensation label.

Does the filing state who receives proceeds from the sales?

The provided excerpt does not state proceeds recipients or use of proceeds. It names Monte Rosa Therapeutics Inc and lists the filer address, but cash‑flow treatment is not specified in the visible text.

Are the amounts shown in the filing confirmed as shares or dollar values?

The excerpt presents numeric values such as 97974.00, 128372.00, and 153759.00 but does not attach explicit unit labels in the visible lines. The filing text labels these under securities and past sales sections without a clear unit in the excerpt.

What dates are relevant in this Form 144 excerpt?

Key dates visible are the RSU grant date 01/02/2025, a related RSU date 01/02/2026, and transaction/reporting dates 01/05/2026 and 01/07/2026 shown near the past sales entries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855643
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Monte Rosa Therapeutics, Inc.
SEC File Number	001-40522
Address of Issuer	321 HARRISON AVENUE SUITE 900 BOSTON MASSACHUSETTS 02118
Phone	617-949-2643
Name of Person for Whose Account the Securities are To Be Sold	Warmuth Markus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Capital Management 500 Boylston Street Suite 1300 Boston MA 02116	5466	97974.00	76242761	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
RSU	01/02/2025	Stock Award	From Issuer			21865	01/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	01/07/2026	5466	128372.00
Markus Warmuth 321 Harrison Ave, Suite 900 Boston MA 02118	Monte Rosa Therapeutics Inc	01/05/2026	10135	153759.00

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Warmuth Markus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)